SCHEMBL13595015

SCHEMBL13595015

CCNS(=O)(=O)Nc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
PKM P14618 5/20 0.51
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
CYP2C9 P11712 1/20 0.46
EDNRA P25101 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
ACP1 P24666 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HTT P42858 1/20 0.43
HIF1A Q16665 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SCN1A P35498 1/20 0.43
SCN1B Q07699 1/20 0.43
SCN5A Q14524 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8088783 0.80 ALDH1A1 (0.50) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL7916147 0.76 ALDH1A1 (0.46) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL2912774 0.76 ALDH1A1 (0.53) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL5710108 0.75 ALDH1A1 (0.50) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL11979598 0.73 ALDH1A1 (0.50) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL1647188 0.72 ALDH1A1 (0.57) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL14009908 0.72 ACP1 (0.61) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL28780801 0.72 LMNA (0.57) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL8796963 0.71 ALDH1A1 (0.49) ALDH1A1PKMLMNATDP1SMN1; SMN2
SCHEMBL12801174 0.71 ALDH1A1 (0.49) ALDH1A1PKMLMNATDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635683-B2 Quinoxalinyl tripeptide hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-12-25 US disclosed
US-20080032936-A1 Quinoxalinyl tripeptide hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS PREP, DNPEP, CTSC ALDH1A1 890/4885PKM 3336/4885LMNA 3533/4885
US-20080032936-A1 Quinoxalinyl tripeptide hepatitis C virus inhibitors VIP, CTSC, PREP ALDH1A1 1229/4885PKM 2907/4885LMNA 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.